ADCT — ADC Therapeutics SA Cashflow Statement
0.000.00%
Last trade - 00:00
- $330.89m
- $519.85m
- $69.56m
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 10-K | 10-K |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -116 | -246 | -230 | -157 | -240 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.423 | 63.8 | 46.5 | 65.9 | 37.2 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -7.17 | 11.6 | -26.4 | -46.6 | 45.9 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -122 | -169 | -233 | -138 | -119 |
Capital Expenditures | -2.15 | -2.81 | -6.38 | -0.687 | -3.22 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.1 | -0.019 | -0.297 | — | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.25 | -2.83 | -6.67 | -0.687 | -3.22 |
Financing Cash Flow Items | — | — | — | -1.31 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 101 | 495 | 267 | -0.897 | 73.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -23.3 | 324 | 27.3 | -140 | -47.8 |